Health Care: Drugs

Clovis Oncology Inc (CLVS: NASDAQ)

$76.46 n/a | n/a%
02/27/15 - 04:00 PM ET
Company Balance Sheet
Dec 2013 Dec 2012 Dec 2011
Cash and Equivalents 323.23M 144.10M 138.24M
Receivables 3.87M 0.00 0.00
Inventories 0.00 0.00 0.00
Other Current Assets 0.00 659.00K 247.00K
Total Current Assets 328.60M 144.87M 141.52M
Property, Plant & Equipment, Gross 1.68M 1.59M 2.17M
Accumulated Depreciation & Depletion 728.00K 508.00K 274.00K
Property, Plant & Equipment, Net 955.00K 1.08M 1.90M
Intangibles 244.52M 0.00 0.00
Other Non-Current Assets 755.00K 38.00K 34.00K
Total Non-Current Assets 321.04M 1.12M 1.93M
Liabilities & Shareholder Equity
Total Assets 649.64M 145.99M 143.44M
Accounts Payable 4.42M 2.30M 3.04M
Short Term Debt 0.00 0.00 0.00
Other Current Liabilities 0.00 0.00 0.00
Total Current Liabilities 20.95M 12.16M 11.00M
Long Term Debt 0.00 0.00 0.00
Deferred Income Taxes 74.96M 0.00 0.00
Other Non-Current Liabilities 55.84M 338.00K 656.00K
Minority Interest 0.00 0.00 0.00
Total Non-Current Liabilities 130.80M 338.00K 656.00K
Total Liabilities 151.75M 12.50M 11.65M
Preferred Stock Equity 0.00 0.00 0.00
Common Stock Equity 497.89M 133.50M 131.79M
Common Par 34.00K 26.00K 22.00K
Additional Paid In Capital 762.17M 317.90M 242.22M
Cumulative Translation Adjustment 0.00 0.00 0.00
Retained Earnings -269.01M -184.48M -110.50M
Treasury Stock 0.00 0.00 0.00
Other Equity Adjustments 4.70M 53.00K 49.00K
Total Capitalization 497.89M 133.50M 131.79M
Total Equity 497.89M 133.50M 131.79M
Total Liabilities & Stock Equity 649.64M 145.99M 143.44M
Total Common Shares Outstanding 33.90M 26.21M 22.38M
Preferred Shares 0.00 0.00 0.00
Treasury Shares 0.00 0.00 0.00
Basic Weighted Shares Outstanding 28.67M 24.92M 3.85M
Diluted Weighted Shares Outstanding 28.67M 24.92M 3.85M
Number of Employees 74 61 57
Number of Part-Time Employees 0 0 0

Portfolios with CLVS

Latest CLVS Headlines from TheStreet

More Financial News for CLVS

Press Releases for CLVS

See All Press Releases
brokerage partners
connect with Stockpickr
Fan us on FaceBook
Follow us on Twitter